+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer



Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer



Anticancer Research 36(8): 4329-4336



The prognostic significance of programmed death ligand 1 (PD-L1) has been reported in non-small cell lung cancer; however, the significance of PD-L1 expression in patients with resected small-cell lung cancer (SCLC) remains to be clarified. Forty patients with SCLC whose resected specimens were available for immunohistochemistry for PD-L1 were evaluated to determine the association between its expression and the clinicopathological factors and prognosis. Among 40 patients, PD-L1 was expressed in tumor cells (TCs) of six (15%), tumor-infiltrating cells (ICs) of 16 (40%), and TCs and/or ICs cells of 18 (45%) patients. Patients with PD-L1-positve ICs and TCs and/or ICs exhibited significantly longer disease-free survival than those without PD-L1-expression (hazard ratio (HR)=0.268; 95% confidence interval (CI)=0.100-0.645; p=0.003 and HR=0.301; 95% CI=0.118-0.702; p=0.005, respectively). This study provides important evidence on the prognostic value of the PD-L1 expression in resected SCLC patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057868093

Download citation: RISBibTeXText

PMID: 27466552


Related references

Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients. Cancer Cytopathology 126(4): 264-274, 2018

Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. Journal of Thoracic Oncology 10(3): 426-430, 2015

Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer. Clinical Lung Cancer 16(5): 385-390, 2015

Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study. Clinical Lung Cancer 19(5): E667-E673, 2018

Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. Medical Oncology 36(6): 49, 2019

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Oncotargets and Therapy 7: 567-573, 2014

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients. Cancer ChemoTherapy and Pharmacology 71(3): 671-680, 2013

Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. Journal of Translational Medicine 14(1): 188, 2016

PD5-3-4: The impact of multiplicity of metastatic nodal stations on survival in surgically resected non-small cell lung cancer patients: Is N2 disease really different from N1 disease?. Journal of Thoracic Oncology 2(8): S479-S480, 2007

Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Annals of Oncology 21(3): 562-567, 2010

Prophylactic cranial irradiation improved the overall survival of patients with surgically resected small cell lung cancer, but not for stage I disease. Lung Cancer 86(3): 334-338, 2014

Prognostic Significance of Programmed Cell Death-Ligand 1 Expression in Patients With Resected Lung Adenocarcinoma. Annals of Thoracic Surgery (): -, 2016

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 36(28): 2872-2878, 2018

Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer. Annals of Thoracic Surgery 84(1): 182-8; Discussion 189-90, 2007

Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. International Journal of Clinical Oncology 23(6): 1052-1059, 2018